If you haven`t bought the 6.20X call:
nor the 4.10X gain:
Then analyzing the options chain and the chart patterns of LLY Eli Lilly prior to the earnings report this week,
I would consider purchasing the 860usd strike price Calls with
an expiration date of 2024-7-19,
for a premium of approximately $9.20.
If these options prove to be profitable prior to the...
Based on my graphic analysis I observe a bearish projection reaching minus 7,5% in the price of this corporation, that is; from $733 it will drop to $678. With a buy exit emerging at $777, it is worth remembering that the exact time the decline will take is unpredictable, the market will simply do its job. We can mention that it will happen within the next 15-20...
I hope you appreciated my rhyme.
So what to say about this.
One main trend line at the moment.
Big support incoming at 580 to 560 range.
Really big support at 108.
The lines in the middle (light green and red) are fairly weak and more likely short term targets.
I assume the long term targets will line up well with the gaps which are marked in orange.
Orange...
Eli Lilly and Company (LLY) witnessed a marginal increase in its last session, closing at $762.91, which is a 0.75% uptick from the prior close. This movement is within a tight consolidation range, hinting at indecision in the market after a notable uptrend.
Volume and Momentum Indicators:
The volume of 842.624K is aligned with the average, suggesting a normal...
🔴 Resistance - 779 🔴
🚀 Target - 788 - 792 🚀
🟢 Support - 777 🟢
🚀 Target - 772 - 768🚀
🚫 Manage Your Risk & Reward As Per Your Risk Management 🚫
🔥🔥 Levels Works Best on 5 - 15 Minutes Time Frame 🔥🔥
❤️❤️ MARKET SECRET ❤️❤️👇
1. TRADE WHAT YOU SEE NOT WHAT YOU ASSUME
2. FOLLOW THE TREND BECAUSE TREND IS YOUR ONLY FRIEND
3. CHART IS SUPREME
4. YOUR ASSUMPTION &...
LLY is looking really good here on the daily chart. It's been consolidating just below ATH on declining volume. It's been respecting the 20 EMA nicely, and MACD is about to flip bullish. definitely one to watch for a breakout.
Eli Lilly aka LLY hit a new all time high again on Wednesday after rival GLP1 drugmaker Novo Nordisk announced it was ending a kidney failure study early for its drug semaglutide due to efficacy data.
Shares of Lilly set a 52 week high of $608.7 before closing the session 5% higher at $605.28. Shares of Novo Nordisk increased as well, rising 6% to settle at...
trendline break + retest.
Possible Head & Shoulders
assumption: Fib# Ext. to 2.618 ( 800 ), retracement to 1.618 (690)
Short 780
Stop 801
Target 690, 650
Risk management is much more important than a good entry point.
I am not a PRO trader.
In my trading plan, the Max Risk of each short term trade should be less than 1% of an account.
🔴 Resistance - 776 🔴
🚀 Target - 782 - 788 🚀
🟢 Support - 773 🟢
🚀 Target - 765 - 758 🚀
🔥🔥 Levels Works Best on 5 Minutes Time Frame 🔥🔥
❤️❤️ MARKET SECRET ❤️❤️👇
1. TRADE WHAT YOU SEE NOT WHAT YOU ASSUME
2. FOLLOW THE TREND BECAUSE TREND IS YOUR ONLY FRIEND
3. CHART IS SUPREME
4. YOUR ASSUMPTION & MOTIONS HAS NO VALUE IN THE MARKET
Our motto is to help each...
In the complex, competitive and unpredictable pharmaceutical, Eli Lilly and Co (LLY) is a notable player that is gaining even more notoriety. The company is currently making significant strides in diabetes care and weight loss medications; however, these advancements have not come without their challenges. It has recently experienced periods of management...
Eli Lilly (LLY) has basically turned sideways since the February 16 High. The dominant pattern is a Channel Up since the March 07 2023 Low and can be divided into 3 Bullish Waves that delivered rallies between +45% and +52%. Every time the price hit the 1D MA50 (blue trend-line), it was a buy opportunity.
The 1D RSI in particular has a Buy Zone, which coincided...
Reasons for bullish bias:
- Entry is at breakout of HH
- DOW theory, SL at last HL
- Respecting trendline
Entry Level: 655.60
Stop Loss Level: 565.08
Take Profit Level 1: 746.12
LLY shown on a daily chart has doubled in the past year with the introduction of new FDA
approved drugs into the market. It has but out a series of favorable earnings reports with
optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume
pumps and just keeps grinding higher. This is because it is in the shadows of big...
Eli Lilly (LLY) gave us the best possible buy entry at the bottom of the Channel Up last time we gave a call on it (December 14 2023, see chart below) and not hit our $705.00 Target but also aggressively broke above the pattern:
In order to grasp the magnitude of that move, this time we zoom out on the 1W time-frame where we see the long-term pattern since...
